Telik, Inc. (NASDAQ:TELK) is seeing shares surging pre-market after it announced that the U.S. Food and Drug Administration has removed the partial hold on TELCYTA clinical trials after a complete review of TELCYTA data by the agency and permits the resumption of TELCYTA clinical development.
This is Telik’s most advanced development program, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non- small cell lung cancer. Its other development candidate that is considered an advanced candidate is TELINTRA in clinical development for the treatment of myelodysplastic syndrome.
As of Friday’s close at $3.46, Telik had a $181.8 million market capitalization. Shares are up over 15% pre-market at $4.05. The 52-week trading range is $2.55 to $20.36, so you can see the reason for the large push pre-market. It trades an average of about 370,000 shares in any given day, but as of the end of September its short interest was more than 9.4 million shares. This sounds like there will be lots of short covering this morning.
Jon C. Ogg
October 15, 2007
Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
